Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Wednesday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $118.08, for a total value of $354,240.00.
• On Monday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $113.57, for a total value of $340,710.00.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $127.18 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm’s fifty day moving average is $117.84 and its 200 day moving average is $113.19. The company has a market cap of $157.79 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Trivium Point Advisory LLC lifted its position in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after buying an additional 83 shares during the period. Binnacle Investments Inc grew its position in shares of Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 83 shares during the period. Rothschild Investment LLC increased its stake in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Hemington Wealth Management lifted its position in Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the period. Finally, Ignite Planners LLC boosted its stake in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after acquiring an additional 86 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Argus raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Morgan Stanley increased their target price on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $129.13.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.